At present, cholinesterase inhibitors (ChEIs: donepezil, rivastigmine, galantamine) and, most recently, the noncompetitive glutamate N-methyl-d-aspartate (NMDA) receptor blocker and adamantine derivative memantine, represent the main pharmacological strategies effective in reducing the progression of cognitive decline and functional loss in people affected by AD. The gene discussed is BCHE; the disease is Mental deterioration.